Obeticholic acid, a farnesoid X receptor agonist, is approved for primary biliary cholangitis and is being tested in cirrhosis due to metabolic dysfunction associated steatohepatitis (Fiorucci et al., 2025). This evidence concerns the gene NR1H4 and Cirrhosis.